CRIS Current Research Information System

FUSAROLI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 882
NA - Nord America 85
AS - Asia 39
AF - Africa 3
SA - Sud America 1
Totale 1.010
Salva come PNG Salva come JPEG
Nazione #
FR - Francia 671
IT - Italia 95
US - Stati Uniti d'America 84
BG - Bulgaria 40
IE - Irlanda 33
DE - Germania 27
CN - Cina 15
AE - Emirati Arabi Uniti 10
SA - Arabia Saudita 9
GB - Regno Unito 5
ES - Italia 3
CZ - Repubblica Ceca 2
IN - India 2
JP - Giappone 2
NL - Olanda 2
CA - Canada 1
CH - Svizzera 1
CL - Cile 1
EG - Egitto 1
FI - Finlandia 1
LV - Lettonia 1
MA - Marocco 1
SE - Svezia 1
SG - Singapore 1
ZA - Sudafrica 1
Totale 1.010
Salva come PNG Salva come JPEG
Città #
Paris 135
Bologna 42
Sofia 40
Dublin 33
Ashburn 19
Florence 10
Rimini 8
Riyadh 7
Cedar Knolls 6
Milan 6
New York 6
Shanghai 6
Pievepelago 5
Boardman 4
Chicago 4
Council Bluffs 3
Frankfurt am Main 3
Hangzhou 3
Mountain View 3
Southend 3
Atlanta 2
Beijing 2
Guangzhou 2
Legnano 2
Los Angeles 2
Minneapolis 2
Padova 2
Prague 2
Sesto Fiorentino 2
Tampa 2
Tokyo 2
Turin 2
Amsterdam 1
Arezzo 1
Cairo 1
Cape Town 1
Cesena 1
Civitella in Val di Chiana 1
Codisotto 1
Columbus 1
Dallas 1
Dalmine 1
Dulles 1
Esslingen am Neckar 1
Ferrara 1
Forlì 1
Genoa 1
Gunzenhausen 1
Henderson 1
Herndon 1
Horben 1
Houston 1
Kenitra 1
Lappeenranta 1
Lo Espejo 1
Maspalomas 1
Massa 1
Medford 1
Mercato Saraceno 1
Miami 1
Modena 1
Mumbai 1
Murcia 1
Naples 1
Omaha 1
Parma 1
Perego 1
Ravenna 1
Riga 1
San Diego 1
Saratoga 1
Seattle 1
Stockholm 1
Torre Boldone 1
Victoria 1
Zurich 1
Totale 414
Salva come PNG Salva come JPEG
Nome #
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, file e1dcb339-a40a-7715-e053-1705fe0a6cc9 640
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies, file 42c8c724-e4be-4b4b-80d7-9e9049eb1e75 46
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System, file 784c07f7-46ac-4a7d-bf08-9b5707e72415 31
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, file e1dcb339-40e3-7715-e053-1705fe0a6cc9 27
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System, file eaca171a-ce1e-41f6-8a42-667f6cbdd357 26
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, file cf7d8fc4-5a7e-40a8-a176-6b5dab7929fe 22
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People, file 463640af-159b-41c1-b35f-8828f6a7a1f8 20
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System, file c0101686-5837-4606-9b30-a38e2ac32429 19
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System, file 4c1ab21e-4a86-468f-b565-8fdfefa93759 17
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis, file 8a74c889-69c7-402d-970d-db76ac58b4e9 16
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System, file e1dcb339-4063-7715-e053-1705fe0a6cc9 15
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis, file 36f230e0-ae1a-4654-902f-423fea08cf99 13
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal, file 69f80cdd-a0a4-4c80-80bc-ab3e66a45bce 13
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry, file 7c410862-ff85-4949-8435-13e6f23a0bd6 10
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System, file 5702d2d6-30cb-47cd-b2b0-49b8bd9b271b 9
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions, file e1dcb336-73cc-7715-e053-1705fe0a6cc9 9
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions, file 2f52c8e7-78d5-4925-861d-717e1395a63c 8
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System, file b0a11f88-d7a2-4b48-a3ae-9841a77cd29c 8
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database, file d6a1690d-3e94-42d9-a26a-e8dcd9683974 7
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, file 46fe2111-4d49-4e50-b12d-b45022612301 6
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry, file e1dcb338-5348-7715-e053-1705fe0a6cc9 5
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct, file 5f13a1ec-8185-4261-bfbe-fadc1cc55f64 4
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System, file 9872e675-f479-47c9-9867-28b38909c2aa 4
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems, file e1dcb33a-2f36-7715-e053-1705fe0a6cc9 4
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System, file 6123cec3-26d5-4009-92d8-fa4f5b109c33 3
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study, file 7b662054-0d67-4bd9-a369-d9a607f9600d 3
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS, file 8f2af6e9-9a45-4b04-9df5-9ae0dc1c377d 3
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems, file e1dcb33a-2f37-7715-e053-1705fe0a6cc9 3
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, file 1be23e9b-59ba-4baf-936b-bd717c99497f 2
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians, file 26a1a4c1-0cf9-45d5-8318-8bb7ac7970d6 2
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians, file 5e7e8e9a-3d1a-415c-9f72-a06312803e25 2
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach, file 864cab47-c7bb-4daa-af2a-434997e52301 2
Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list, file e1dcb338-be9a-7715-e053-1705fe0a6cc9 2
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study, file 185cc669-d236-42f3-9712-502b2306e2b3 1
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct, file 1ad0bad2-969b-49a3-b81a-60cf351e6fa4 1
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors, file 38b324ba-fc8b-462d-9bd0-b1d4bf834d83 1
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database, file 5ea0c2c6-4f2b-46bc-bee1-dd09ab474172 1
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System, file 8ef097d0-f855-4218-b294-c55e8ab83083 1
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors, file 92d4b2f5-fc74-4494-9820-0fe9d791828b 1
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS, file af3cf9ff-f9ac-44b8-8ee6-eb94b2f28eaf 1
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System, file c55c04d5-9141-4d2a-ac6d-aed2ce766968 1
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System, file df709887-9684-4a0d-86e6-5c555ac5ad35 1
Transparency and robustness of safety signals, file e688d55b-84c2-4cd3-ba84-147a1d6ddb7e 1
Totale 1.011
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.836
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.836
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227 0 0 0 0 0 0 0 0 2 1 3 1
2022/2023109 1 0 2 2 3 5 9 15 38 9 21 4
2023/2024895 9 9 27 32 10 543 14 138 97 16 0 0
Totale 1.011